Subcutaneous Tissue Irrigation With Povidone Iodine in Decreasing the Rate of Surgical Site Infection Following Cesarean Section
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03549702 |
|
Recruitment Status :
Completed
First Posted : June 8, 2018
Last Update Posted : June 8, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Surgical Site Infection | Drug: Povidone iodine 1% solution | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | Subcutaneous Tissue Irrigation With Povidone Iodine in Decreasing the Rate of Surgical Site Infection Following Cesarean Section (Randomized Control Trial) |
| Actual Study Start Date : | January 1, 2017 |
| Actual Primary Completion Date : | February 28, 2018 |
| Actual Study Completion Date : | March 3, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Povidone irrigation Group
Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
|
Drug: Povidone iodine 1% solution
irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure |
|
No Intervention: Control Group
Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
|
- Surgical site infection up to 14 days following elective caesarian section. [ Time Frame: 14 Days ]
- Infection involves only skin and subcutaneous tissue of this incision.
- Occurs within 14 days after the operative procedure.
-
Includes at least one of the following:
- purulent drainage is present (culture documentation not required)
- organisms are isolated from fluid/tissue of the superficial incision
- at least one sign of inflammation (eg, pain or tenderness, induration, erythema, local warmth of the wound) is present.
- the wound is deliberately opened by the surgeon
- the surgeon or clinician declares the wound infected.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age: from 20 to 35 old years.
- Elective cesarean section.
- Caesarean section time from skin incision to skin closure less than 60 minutes.
- Preoperative Hemoglobin more than 10 gm /dl.
- Body Mass Index: 20_30 Kg/m2 .
Exclusion Criteria:
- Body Mass Index: <20 or >30 Kg/m2.
- Diabetic patient.
- Feverish patient.
- Patient using steroids for chronic illness.
- Hypertension chronic or with pregnancy.
- Prelabour rupture of membranes.
- Difference in pre and postoperative hemoglobin more than 10%.
- Patients have a Coagulopathy disorder.
- Multiple pregnancy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03549702
| Egypt | |
| Faculty of Medicine - Ain SHams University | |
| Cairo, Egypt, 202 | |
| Principal Investigator: | George Azmy, MBBCH | Specialist of Obstetrics and Gynecology |
| Responsible Party: | George Adel Azmy, Specialist in Obstetrics and Gynecology, Ain Shams University |
| ClinicalTrials.gov Identifier: | NCT03549702 |
| Other Study ID Numbers: |
PovidIodCS |
| First Posted: | June 8, 2018 Key Record Dates |
| Last Update Posted: | June 8, 2018 |
| Last Verified: | May 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Infections Communicable Diseases Surgical Wound Infection Disease Attributes Pathologic Processes Wound Infection Postoperative Complications |
Povidone-Iodine Povidone Plasma Substitutes Blood Substitutes Anti-Infective Agents, Local Anti-Infective Agents |

